Does MOTS-c bind AMPK directly?

No. It acts upstream, on the folate cycle, and AMPK responds to the resulting AICAR accumulation.

Is this the same mechanism as metformin?

No. Both activate AMPK indirectly, but metformin inhibits complex I and raises the AMP-to-ATP ratio, while MOTS-c works through one-carbon metabolism.

5-aminoimidazole-4-carboxamide ribonucleotide, an intermediate of purine synthesis that acts as an AMP mimetic and activates AMPK once phosphorylated to ZMP.

MOTS-c (Mitochondrial Peptide)

MOTS-c Mechanism: AMPK Activation via the Folate Cycle

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

MOTS-c activates AMP-activated protein kinase without raising the AMP-to-ATP ratio. It inhibits the folate cycle and de novo purine biosynthesis, causing the endogenous AMPK activator AICAR to accumulate. AMPK activation follows from that accumulation, making the mechanism metabolite-mediated rather than direct.

Key facts

Target pathway: Folate cycle / de novo purine biosynthesis
Accumulating metabolite: AICAR
Downstream kinase: AMPK
Canonical AMPK trigger: Rising AMP:ATP ratio — not used here
Reported downstream effect: GLUT4 translocation
Primary reference: Lee et al., Cell Metab 2015 (PMID 25738459)

What AMPK is and why it matters

AMP-activated protein kinase is the cell's principal energy sensor. When energy charge falls, AMPK switches the cell from anabolic to catabolic behaviour — increasing glucose uptake and fatty-acid oxidation, suppressing synthetic pathways. It is normally activated by AMP and ADP binding directly to its gamma subunit, which is why AMPK activation is usually understood as a direct readout of the AMP-to-ATP ratio.

The route MOTS-c takes instead

MOTS-c does not raise the AMP-to-ATP ratio. It interferes with the folate cycle, the one-carbon metabolic pathway that supplies carbon units for de novo purine biosynthesis. Blocking that pathway causes AICAR — an intermediate of purine synthesis and a well-characterised endogenous AMPK activator — to build up. AMPK then responds to AICAR. The peptide never touches AMPK itself.

Research material referenced

MOTS-C 10mg — third-party HPLC tested

View — £24.99

Why AICAR is the relevant intermediate

AICAR is structurally an AMP mimetic. Once phosphorylated inside the cell to ZMP, it binds the same regulatory site on AMPK that AMP occupies. This is not a novel mechanism invented for MOTS-c — AICAR has been used as a laboratory AMPK activator for decades. What MOTS-c does is raise it endogenously by constricting the pathway that consumes it.

How this differs from metformin

Metformin is also an indirect AMPK activator, but by a different route: it inhibits mitochondrial complex I, which lowers ATP production and genuinely does raise the AMP-to-ATP ratio. MOTS-c arrives at the same kinase through one-carbon metabolism without impairing respiration. Two indirect activators, two entirely different upstream mechanisms.

Reported downstream effects

The 2015 paper reported GLUT4 translocation and effects on glucose handling in mouse models, consistent with AMPK activation. Later work has examined mitochondrial respiration in tissue models. All of this is preclinical, and the effects are reported for the models studied rather than established for humans.

Why the indirectness is scientifically interesting

A mitochondrially encoded peptide that regulates a cytosolic energy sensor through a one-carbon metabolic pathway is a genuinely unusual signalling architecture. It connects mitochondrial gene expression to nuclear-genome-encoded metabolism through a diffusible small-molecule intermediate, which is a different kind of communication from a receptor-ligand interaction.

Extended research context

The MOTS-c (Mitochondrial Peptide) deep dive

Deep dive: why a peptide encoded in mitochondrial DNA is unusual

The human mitochondrial genome is 16,569 base pairs encoding 37 genes, and was considered fully characterised by the 1980s: thirteen respiratory-chain proteins, twenty-two transfer RNAs, two ribosomal RNAs. MOTS-c is encoded by a short open reading frame nested inside the 12S rRNA gene — sequence already annotated as doing something else, which is exactly why it went unnoticed. Humanin, found in 2001 inside the 16S rRNA gene, established that the genome held more than its annotation suggested; MOTS-c was found in 2015 by looking deliberately. The implication is that the mitochondrion encodes and releases signalling molecules of its own, rather than only executing instructions sent from the nucleus.

Deep dive: AMPK activation without touching AMPK

AMPK is normally activated when AMP and ADP bind its gamma subunit, making it a direct sensor of the AMP-to-ATP ratio. MOTS-c does not raise that ratio and does not bind the kinase. It inhibits the folate cycle, the one-carbon pathway feeding de novo purine biosynthesis, and the intermediate AICAR accumulates as a result. AICAR is an AMP mimetic — phosphorylated to ZMP, it binds the same regulatory site AMP occupies. So the peptide reaches a cytosolic energy sensor through one-carbon metabolism and a diffusible small molecule, which is a materially different architecture from a receptor-ligand interaction, and different again from metformin's inhibition of complex I.

Deep dive: reading a preclinical literature honestly

Roughly 250 indexed papers exist, and the overwhelming majority are cell and rodent studies. Where humans appear, the work is generally observational: measuring circulating concentrations and correlating them with age, fitness or metabolic state. The 2021 Nature Communications paper is the clearest example of the structure — the human arm measured MOTS-c before and after exercise, finding roughly a 12-fold rise in skeletal muscle against 1.6-fold in circulation, while the interventional work was done in mice. Two inferences the secondary literature routinely makes and the primary literature does not support: that a correlation between low concentrations and poor metabolic health establishes direction, and that a molecule which rises during exercise would reproduce exercise if administered.

Research applications

▸Study of mitochondrial-derived peptides and retrograde signalling
▸AMPK pathway research through non-canonical activation
▸One-carbon and folate-cycle metabolism models
▸Exercise physiology and mitochondrial bioenergetics research
▸Ageing biology and mitochondrial genome expression studies

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓Expect methionine oxidation as the primary degradation route (+16 Da per residue)
✓No reducing agent needed — the sequence contains no cysteine
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles
✓Check mass spectrometry for +16 and +32 satellites before relying on a batch

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Reading exercise induction as proof that administration mimics exercise

Fix: The papers report that exercise raises MOTS-c. The reverse inference is not supported and is not claimed.

✗ Treating human observational data as interventional evidence

Fix: Human work measures endogenous concentrations; administration studies were conducted in mice.

✗ Assuming MOTS-c has a cell-surface receptor like humanin

Fix: No receptor is established. Its characterised activity is intracellular.

✗ Storing reconstituted material as though it were as stable as the powder

Fix: Solution-phase material is subject to hydrolysis and oxidation; the lyophilised form is far more stable.

✗ Overlooking WADA status in athlete-adjacent research

Fix: MOTS-c is on the prohibited list; this is relevant to any research context involving competitors.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does MOTS-c bind AMPK directly?: No. It acts upstream, on the folate cycle, and AMPK responds to the resulting AICAR accumulation.
Is this the same mechanism as metformin?: No. Both activate AMPK indirectly, but metformin inhibits complex I and raises the AMP-to-ATP ratio, while MOTS-c works through one-carbon metabolism.
What is AICAR?: 5-aminoimidazole-4-carboxamide ribonucleotide, an intermediate of purine synthesis that acts as an AMP mimetic and activates AMPK once phosphorylated to ZMP.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More MOTS-c (Mitochondrial Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum